Assessing the Use of Dapagliflozin in Patients With Type 2 Diabetes Hospitalized With COVID-19
July 5th 2021Mikhail Kosiborod, MD, cardiologist and vice president of research at Saint Luke's Health in Kansas City, discussed how the phase 3 DARE-19 trial was conducted to assess dapagliflozin in patients with type 2 diabetes hospitalized with COVID-19.
Safety Profile of Dapagliflozin Among Patients With Type 2 Diabetes Hospitalized With COVID-19
July 2nd 2021Mikhail Kosiborod, MD, cardiologist and vice president of research at Saint Luke's Health in Kansas City, discussed the findings around the safety profile of dapagliflozin in patients with and without type 2 diabetes hospitalized with COVID-19 during the DARE-19 trial.
Assessing Adverse Events From Investigational Dose of Semaglutide Injection for Type 2 Diabetes
July 2nd 2021Michael Radin, MD, executive director, Diabetes Cardio Renal Medical Director Team, Medical Affairs, Novo Nordisk, discusses the adverse events experienced by patients during the SUSTAIN FORTE phase 3 clinical trial evaluating an investigational 2 mg dose of semaglutide injection in adults with type 2 diabetes.
The Impact of ACCC’s Multiple Myeloma Dispensing Project on the Field
July 1st 2021Kirollos Hanna, PharmD, BCPS, BCOP, assistant professor of pharmacy at the Mayo Clinic College of Medicine and the oncology pharmacy manager at M Health Fairview - Maple Grove, discusses the potential impact of ACCC's Multiple Myeloma Dispensing Project on the field.
Efficacy, Safety of an Investigational Dose of Semaglutide Injection in Adults With Type 2 Diabetes
June 30th 2021Michael Radin, MD, executive director, Diabetes Cardio Renal Medical Director Team, Medical Affairs, Novo Nordisk, discusses the findings around the efficacy and safety of the 2 mg dose of semaglutide for the treatment of type 2 diabetes.
The Future of Pharmaceuticals and the FDA Pipeline
June 30th 2021Chad Landmon, attorney and chair of Axinn’s Intellectual Property and FDA Practice Groups, discusses upcoming clinical trials on COVID-19 booster shots, the possibility of cancer vaccines, and the future of pharmaceuticals and FDA approvals.
Key Events in the FDA Pipeline During COVID-19
June 29th 2021Pharmacy Times spoke with Chad Landmon, attorney and chair of Axinn’s Intellectual Property and FDA Practice Groups, about key events in the FDA pipeline, such as Emergency Use Authorizations during COVID-19 and the future of narrowed approvals.